GD2 CAR T-cell therapy for diffuse midline gliomas: A paradigm shift in treatment

GD2 CAR T-cell therapy for diffuse midline gliomas: A paradigm shift in treatment - Diffuse midline gliomas (DMGs), including diffuse intrinsic pontine gliomas (DIPGs), are highly aggressive brain tumours with limited treatment options and poor prognosis. Standard therapies, such as radiation and chemotherapy, offer only marginal survival benefits. Chimeric antigen receptor (CAR) T-cell therapy targeting disialoganglioside GD2 has emerged as a novel immunotherapeutic approach, leveraging its high expression on DMG cells. Preclinical and early clinical studies have demonstrated promising antitumor activity, with GD2 CAR T-cells successfully trafficking into the central nervous system and inducing tumour regression. However, challenges such as the immunosuppressive tumour microenvironment, potential neurotoxicity, and optimal delivery strategies remain. This short communication explores the rationale, recent advances, and ongoing challenges of GD2 CAR T-cell therapy in DMGs. While further research is needed, GD2-directed CAR T-cell therapy holds significant potential to transform the treatment landscape and improve outcomes for patients with these devastating tumours. Keywords: Diffuse midline gliomas (DMGs); CAR T-cell therapy; Disialoganglioside GD2.